A molecular engineered NIR-II fluorescence agent with enhanced radiative and non-radiative decay for precision prostate cancer bone metastasis theranostics
Source abstract
Abstract
The rational design of organic phototheranostic agents that combine diagnostic and therapeutic capabilities for cancer treatment remains challenging due to the inherent competition between radiative and non-radiative energy dissipation pathways. Herein, a novel molecule, TQP-TTPA, is strategically designed by incorporating a bulky electron donor and extended π-bridge, resulting in red-shifted absorption and emission in the second near-infrared window (NIR-II), along with prominent NIR-IIa emission (1300 - 1500 nm), a high NIR-II extinction coefficient, and enhanced NIR-IIa fluorescence brightness and photothermal conversion efficiency (43.8%). These favorable properties are attributed to the strong donor-acceptor (D-A) interaction and enhanced intramolecular motion. Quantum chemical calculations provide insights into the excited-state energy dissipation mechanism and the role of intramolecular motion in modulating photophysical behavior. Furthermore, the femtosecond transient absorption (fs-TA) spectroscopy reveals that the performance enhancement originates from efficient intramolecular charge transfer (ICT) and promoted intramolecular motion by rational donor/π-bridge engineering. Based on these advantages, alendronate-functionalized TQP-TTPA nanoparticles (TQP-TTPA@ALD NPs) are developed for precise and high-resolution NIR-II fluorescence (FLI), photoacoustic (PAI), and phototherml (PTI) trimodal imaging-guided high-efficiency photothermal therapy (PTT) of prostate cancer bone metastases. This work offers a molecular-level design strategy for organic phototheranostics with tunable radiative/non-radiative decay balance, bridging fundamental photophysics and precision cancer theranostics. Three TQP-based D-A-D dyes were rationally designed through molecular engineering to achieve improved phototheranostics. Quantum and fs-TA analyses reveal TQP-TTPA's exceptional photothermal performance stems from enhanced D-A interaction and molecular rotation. Further alendronate-functional NPs (TQP-TTPA@ALD NPs) demonstrate precise and high-resolution trimodal (NIR-II FL/PA/PT) imaging-guided high-efficiency PTT in prostate cancer bone metastases. This work provides molecular-level insights into photothermal enhancement while advan cing metastatic cancer theranostics.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Luminescence Properties of Advanced Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Prostate cancer10.1001/jama.2025.0228 ↗
2. Prostate cancer10.1038/s41572-020-00243-0 ↗
3. Prostate cancer screening … and other research
4. Striving toward a cure for prostate cancer10.1200/JCO.2015.66.3146 ↗
5. Screening for prostate cancer: is the third trial the charm?10.1001/jama.2018.0153 ↗
6. Adjuvant vs salvage radiation therapy for high-risk prostate cancer following radical prostatectomy10.1001/jamaoncol.2020.0565 ↗
7. Novel therapeutic targets on the horizon: an analysis of clinical trials on therapies for bone metastasis in prostate cancer10.3390/cancers16030627 ↗
8. Clinical challenges in prostate cancer management: metastatic bone-tropism and the role of circulating tumor cells10.1016/j.canlet.2024.217310 ↗
9. Optimizing skeletal-related events prevention in patients with advanced prostate cancer, Asia Pac
10. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care ontario guideline10.1200/JCO.19.03148 ↗
11. As aggregation-induced emission meets with noncovalent conformational locks: subtly regulating NIR-II molecules for multimodal imaging-navigated synergistic therapies10.1002/anie.202413219 ↗
12. Second near-infrared photothermal materials for combinational nanotheranostics10.1039/D0CS00664E ↗
13. Small molecular NIR-II fluorophores for cancer phototheranostics
14. Side-chain-tuned molecular packing allows concurrently boosted photoacoustic imaging and NIR-II fluorescence10.1002/anie.202117433 ↗
15. CH-π interaction-induced triplet excimer for enhanced phosphorescence bio-imaging, Cell Rep
16. Recent advances in organic phosphorescent materials for bioimaging, Biomed
17. Regulating triplet excitons of organic luminophores for promoted bioimaging10.2174/0109298673301552240305064259 ↗
18. A targeted activatable NIR-IIb nanoprobe for highly sensitive detection of ischemic stroke in a photothrombotic stroke model10.1002/adhm.202001544 ↗
19. Advanced fluorescence imaging technology in the near-infrared-II window for biomedical applications10.1021/jacs.0c07022 ↗
20. Challenges and opportunities for intravital near-infrared fluorescence imaging technology in the second transparency window10.1021/acsnano.8b07536 ↗
21. Au-doped Ag2Te quantum dots with bright NIR-IIb fluorescence for in situ monitoring of angiogenesis and arteriogenesis in a hindlimb ischemic model10.1002/adma.202103953 ↗
22. NIR-II phototherapy agents with aggregation-induced emission characteristics for tumor imaging and therapy10.1016/j.biomaterials.2022.121535 ↗
23. Highly bright aggregation-induced emission nanodots for precise photoacoustic/NIR-II fluorescence imaging-guided resection of neuroendocrine neoplasms and sentinel lymph nodes10.1016/j.biomaterials.2022.121780 ↗
24. Versatile types of inorganic/organic NIR-IIa/IIb fluorophores: from strategic design toward molecular imaging and theranostics10.1021/acs.chemrev.1c00553 ↗
25. Molecular programming of NIR-IIb-emissive semiconducting small molecules for in vivo high-contrast bioimaging beyond 1500 nm10.1002/adma.202201263 ↗
26. Transformable hybrid semiconducting polymer nanozyme for second near-infrared photothermal ferrotherapy10.1038/s41467-020-15730-x ↗
27. A versatile 980 nm absorbing aggregation-induced emission luminogen for NIR-II imaging-guided synergistic photo-immunotherapy against advanced pancreatic cancer10.1002/adfm.202205371 ↗
28. AIE-augmented NIR-II-emissive supramolecular metallacycle nanoplatform for tumor microenvironment-responsive chemo-photothermal-immunotherapy
29. An all-round athlete on the track of phototheranostics: subtly regulating the balance between radiative and nonradiative decays for multimodal imaging-guided synergistic therapy10.1002/adma.202003210 ↗
30. Fluorination enhances NIR-II fluorescence of polymer dots for quantitative brain tumor imaging10.1002/anie.202007886 ↗
31. Three-pronged attack by homologous far-red/NIR AIEgens to achieve 1+1+1>3 synergistic enhanced photodynamic therapy10.1002/anie.202000740 ↗
32. Albumin tailoring fluorescence and photothermal conversion effect of near-infrared-II fluorophore with aggregation-induced emission characteristics10.1038/s41467-019-10056-9 ↗
33. Increasing molecular planarity through donor/side-chain engineering for improved NIR-IIa fluorescence imaging and NIR-II photothermal therapy under 1064 nm10.1002/anie.202215372 ↗
34. Planar and twisted molecular structure leads to the high brightness of semiconducting polymer nanoparticles for NIR-IIa fluorescence imaging10.1021/jacs.0c07193 ↗
35. Bandgap modulation and lipid intercalation generates ultrabright D–A–D-based zwitterionic small-molecule nanoagent for precise NIR-II excitation phototheranostic applications10.1002/adfm.202208463 ↗
36. Side chain phenyl isomerization-induced spatial conjugation for achieving efficient near-infrared II phototheranostic agents10.1002/anie.202419785 ↗
37. Boron–oxygen chelation-enabled aza-BODIPY J-Aggregates: NIR-II imaging and photothermal therapy for single-dose tumor ablation10.1002/smll.202504607 ↗
38. D-A type NIR-II organic molecules: strategies for the enhancement fluorescence brightness and applications in NIR-II fluorescence imaging-navigated photothermal therapy
39. An sp-hybridized all-carboatomic ring, cyclo[18]carbon: electronic structure, electronic spectrum, and optical nonlinearity10.1016/j.carbon.2020.05.023 ↗
40. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy, Phy10.1039/b508541a ↗
41. Aggregation effects on the optical emission of 1,1,2,3,4,5-hexaphenylsilole (HPS): a QM/MM study10.1021/jp5021017 ↗
42. Structural and theoretical insights into the AIE attributes of phosphindole oxide: the balance between rigidity and flexibility10.1002/chem.201405902 ↗
43. Ultrafast transient absorption spectroscopy: principles and application to photosynthetic systems10.1007/s11120-009-9454-y ↗
44. Rational design of polymethine dyes with NIR-II emission and high photothermal conversion efficiency for multimodal-imaging-guided photo-immunotherapy10.1002/adma.202210179 ↗
45. Strategies to address key challenges of metallacycle/metallacage-based supramolecular coordination complexes in biomedical applications10.1039/D3CS00926B ↗
46. Manipulating nonradiative decay channel by intermolecular charge transfer for exceptionally improved photothermal conversion10.1021/acsnano.9b06208 ↗
47. Manipulating the dynamics of dark excited states in organic materials for phototheranostics10.1021/acs.accounts.0c00688 ↗
48. Ultrafast spectroscopy: state of the art and open challenges10.1021/jacs.9b10533 ↗
49. Excimer-mediated ultrafast intermolecular nonradiative decay enables giant photothermal performance for optimized phototheranostic
50. Configuration-mediated efficient non-radiative transition for R848-assisted photothermal immunotherapy to inhibit tumor growth and metastasis by an in situ tumor vaccine strategy10.1002/anie.202417871 ↗
51. Alendronate-functionalized porous nano-crystalsomes mitigate osteolysis and consequent inhibition of tumor growth in a tibia-induced metastasis model10.1016/j.jconrel.2024.06.009 ↗
52. Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis10.1021/acsnano.9b00097 ↗
53. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer10.4103/aja.aja_12_18 ↗
54. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer10.1016/j.jconrel.2014.10.012 ↗
55. Unleashing the power of magnetic particle imaging: tailored magnetic nanoparticles for ultrasensitive detection of bone metastases in prostate cancer10.1002/adma.202508495 ↗
56. Alendronate conjugate for targeted delivery to bone-forming prostate cancer10.1016/j.talanta.2023.124308 ↗
57. Engineered multifunctional nanomedicine for simultaneous stereotactic chemotherapy and inhibited osteolysis in an orthotopic model of bone metastasis10.1002/adma.201605754 ↗
58. NIR-II excitation phototheranostic platform for synergistic photothermal therapy/chemotherapy/chemodynamic therapy of breast cancer bone metastases10.1002/advs.202204718 ↗